Treatment related factors and inhibitor development in children with severe haemophilia A

P S Maclean, M Richards, M Williams, P Collins, R Liesner, D M Keeling, T Yee, A M Will, D Young, E A Chalmers, Paediatric Working Party of UKHCDO

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

With the advent of modern factor replacement therapy the most important remaining obstacle to successful treatment in haemophilia A is the development of inhibitory antibodies against Facto VIII (FVIII). This retrospective case control study examined genetic variables and early treatment patterns in severe haemophilia A patients who subsequently developed clinically significant inhibitors to FVIII compared with matched controls who did not. Seventy eight inhibitor patients were identified from 13 UK centers over 25 years (1982-2007). For each case an age matched control was selected. Data on potential genetic and treatment related risk factors were collected for cases and controls. Treatment related data was collected for the first 50 exposure days (EDs) for controls or up to inhibitor development for cases. Risk factors were compared for significance by univariate and multivariate analysis. Of the genetic risk factors, major defects in the FVIII gene and non-caucasian ethnicity were each responsible for approximately 5-fold increases in inhibitor risk. When treatment related variables are considered, high intensity treatment increased inhibitor risk around 2.5 fold whether represented by the presence of peak treatment moments or by high overall treatment frequency. This finding was significant regardless of the timing of the high intensity treatment. Periods of intense treatment associated with surgery for porta-cath insertion were however not found to be associated with increased inhibitor risk. No association was shown between inhibitor development and age at first FVIII exposure, type of FVIII product, or the use of regular prophylaxis. This study confirms treatment-related factors as important risks for inhibitor development in Haemophilia A.
LanguageEnglish
Pages282-287
Number of pages6
JournalHaemophilia
Volume17
Issue number2
Early online date11 Nov 2010
DOIs
Publication statusPublished - Mar 2011

Fingerprint

Hemophilia A
Child Development
Therapeutics
Case-Control Studies
Multivariate Analysis

Keywords

  • autoantibodies
  • blood coagulation factor inhibitors
  • case-control studies
  • child
  • child, preschool
  • DNA mutational analysis
  • factor VIII
  • genotype
  • hemophilia A
  • humans
  • infant
  • multivariate analysis
  • mutation
  • retrospective studies
  • risk factors

Cite this

Maclean, P. S., Richards, M., Williams, M., Collins, P., Liesner, R., Keeling, D. M., ... Paediatric Working Party of UKHCDO (2011). Treatment related factors and inhibitor development in children with severe haemophilia A. Haemophilia, 17(2), 282-287. https://doi.org/10.1111/j.1365-2516.2010.02422.x
Maclean, P S ; Richards, M ; Williams, M ; Collins, P ; Liesner, R ; Keeling, D M ; Yee, T ; Will, A M ; Young, D ; Chalmers, E A ; Paediatric Working Party of UKHCDO. / Treatment related factors and inhibitor development in children with severe haemophilia A. In: Haemophilia. 2011 ; Vol. 17, No. 2. pp. 282-287.
@article{b08dd9218707473892bc9ee6fa638991,
title = "Treatment related factors and inhibitor development in children with severe haemophilia A",
abstract = "With the advent of modern factor replacement therapy the most important remaining obstacle to successful treatment in haemophilia A is the development of inhibitory antibodies against Facto VIII (FVIII). This retrospective case control study examined genetic variables and early treatment patterns in severe haemophilia A patients who subsequently developed clinically significant inhibitors to FVIII compared with matched controls who did not. Seventy eight inhibitor patients were identified from 13 UK centers over 25 years (1982-2007). For each case an age matched control was selected. Data on potential genetic and treatment related risk factors were collected for cases and controls. Treatment related data was collected for the first 50 exposure days (EDs) for controls or up to inhibitor development for cases. Risk factors were compared for significance by univariate and multivariate analysis. Of the genetic risk factors, major defects in the FVIII gene and non-caucasian ethnicity were each responsible for approximately 5-fold increases in inhibitor risk. When treatment related variables are considered, high intensity treatment increased inhibitor risk around 2.5 fold whether represented by the presence of peak treatment moments or by high overall treatment frequency. This finding was significant regardless of the timing of the high intensity treatment. Periods of intense treatment associated with surgery for porta-cath insertion were however not found to be associated with increased inhibitor risk. No association was shown between inhibitor development and age at first FVIII exposure, type of FVIII product, or the use of regular prophylaxis. This study confirms treatment-related factors as important risks for inhibitor development in Haemophilia A.",
keywords = "autoantibodies, blood coagulation factor inhibitors, case-control studies, child, child, preschool, DNA mutational analysis, factor VIII, genotype, hemophilia A, humans, infant, multivariate analysis, mutation, retrospective studies, risk factors",
author = "Maclean, {P S} and M Richards and M Williams and P Collins and R Liesner and Keeling, {D M} and T Yee and Will, {A M} and D Young and Chalmers, {E A} and {Paediatric Working Party of UKHCDO}",
note = "{\circledC} 2010 Blackwell Publishing Ltd.",
year = "2011",
month = "3",
doi = "10.1111/j.1365-2516.2010.02422.x",
language = "English",
volume = "17",
pages = "282--287",
journal = "Haemophilia",
issn = "1351-8216",
number = "2",

}

Maclean, PS, Richards, M, Williams, M, Collins, P, Liesner, R, Keeling, DM, Yee, T, Will, AM, Young, D, Chalmers, EA & Paediatric Working Party of UKHCDO 2011, 'Treatment related factors and inhibitor development in children with severe haemophilia A' Haemophilia, vol. 17, no. 2, pp. 282-287. https://doi.org/10.1111/j.1365-2516.2010.02422.x

Treatment related factors and inhibitor development in children with severe haemophilia A. / Maclean, P S; Richards, M; Williams, M; Collins, P; Liesner, R; Keeling, D M; Yee, T; Will, A M; Young, D; Chalmers, E A; Paediatric Working Party of UKHCDO.

In: Haemophilia, Vol. 17, No. 2, 03.2011, p. 282-287.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment related factors and inhibitor development in children with severe haemophilia A

AU - Maclean, P S

AU - Richards, M

AU - Williams, M

AU - Collins, P

AU - Liesner, R

AU - Keeling, D M

AU - Yee, T

AU - Will, A M

AU - Young, D

AU - Chalmers, E A

AU - Paediatric Working Party of UKHCDO

N1 - © 2010 Blackwell Publishing Ltd.

PY - 2011/3

Y1 - 2011/3

N2 - With the advent of modern factor replacement therapy the most important remaining obstacle to successful treatment in haemophilia A is the development of inhibitory antibodies against Facto VIII (FVIII). This retrospective case control study examined genetic variables and early treatment patterns in severe haemophilia A patients who subsequently developed clinically significant inhibitors to FVIII compared with matched controls who did not. Seventy eight inhibitor patients were identified from 13 UK centers over 25 years (1982-2007). For each case an age matched control was selected. Data on potential genetic and treatment related risk factors were collected for cases and controls. Treatment related data was collected for the first 50 exposure days (EDs) for controls or up to inhibitor development for cases. Risk factors were compared for significance by univariate and multivariate analysis. Of the genetic risk factors, major defects in the FVIII gene and non-caucasian ethnicity were each responsible for approximately 5-fold increases in inhibitor risk. When treatment related variables are considered, high intensity treatment increased inhibitor risk around 2.5 fold whether represented by the presence of peak treatment moments or by high overall treatment frequency. This finding was significant regardless of the timing of the high intensity treatment. Periods of intense treatment associated with surgery for porta-cath insertion were however not found to be associated with increased inhibitor risk. No association was shown between inhibitor development and age at first FVIII exposure, type of FVIII product, or the use of regular prophylaxis. This study confirms treatment-related factors as important risks for inhibitor development in Haemophilia A.

AB - With the advent of modern factor replacement therapy the most important remaining obstacle to successful treatment in haemophilia A is the development of inhibitory antibodies against Facto VIII (FVIII). This retrospective case control study examined genetic variables and early treatment patterns in severe haemophilia A patients who subsequently developed clinically significant inhibitors to FVIII compared with matched controls who did not. Seventy eight inhibitor patients were identified from 13 UK centers over 25 years (1982-2007). For each case an age matched control was selected. Data on potential genetic and treatment related risk factors were collected for cases and controls. Treatment related data was collected for the first 50 exposure days (EDs) for controls or up to inhibitor development for cases. Risk factors were compared for significance by univariate and multivariate analysis. Of the genetic risk factors, major defects in the FVIII gene and non-caucasian ethnicity were each responsible for approximately 5-fold increases in inhibitor risk. When treatment related variables are considered, high intensity treatment increased inhibitor risk around 2.5 fold whether represented by the presence of peak treatment moments or by high overall treatment frequency. This finding was significant regardless of the timing of the high intensity treatment. Periods of intense treatment associated with surgery for porta-cath insertion were however not found to be associated with increased inhibitor risk. No association was shown between inhibitor development and age at first FVIII exposure, type of FVIII product, or the use of regular prophylaxis. This study confirms treatment-related factors as important risks for inhibitor development in Haemophilia A.

KW - autoantibodies

KW - blood coagulation factor inhibitors

KW - case-control studies

KW - child

KW - child, preschool

KW - DNA mutational analysis

KW - factor VIII

KW - genotype

KW - hemophilia A

KW - humans

KW - infant

KW - multivariate analysis

KW - mutation

KW - retrospective studies

KW - risk factors

UR - http://www.scopus.com/inward/record.url?scp=79951778636&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2516.2010.02422.x

DO - 10.1111/j.1365-2516.2010.02422.x

M3 - Article

VL - 17

SP - 282

EP - 287

JO - Haemophilia

T2 - Haemophilia

JF - Haemophilia

SN - 1351-8216

IS - 2

ER -

Maclean PS, Richards M, Williams M, Collins P, Liesner R, Keeling DM et al. Treatment related factors and inhibitor development in children with severe haemophilia A. Haemophilia. 2011 Mar;17(2):282-287. https://doi.org/10.1111/j.1365-2516.2010.02422.x